Related Experiment Video
Updated: Jun 26, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Mutactimycin E, a new anthracycline antibiotic with gram-positive activity
D Craig Hopp1, John Rabenstein, Joshua Rhea
1AMRI, Bothell Research Center, Bothell, WA 98011, USA.
Abstract:
Resistance to currently available antibiotics has become a widely recognized crisis in the medical community. To address this, many companies and researchers are refocusing their attention towards natural products, which have an excellent track record of producing effective antibacterial drugs. The AMRI natural product library was screened for activity against multi-drug resistant Staphylococcus aureus (MDRSA). The active samples were counter screened for cytotoxicity against the human hepatocellular carcinoma HepG2 cell line to determine an in vitro therapeutic index (in vitro TI). Those samples with a high in vitro TI were selected for fractionation and dereplication. This led to the discovery of a new anthracycline structure. This metabolite, named mutactimycin E (1), exhibited moderate activity against several gram positive organisms. Here we report the isolation, structure elucidation and biological activities of this new compound.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance
Anthelminthic Agents
Inhibitors of Gram-positive Cell Wall Synthesis
Mechanism of Antibiotic Resistance in MRSA
Drugs that Destabilize Microtubules
